ANDA 78879, held by Heritage. Temozolomide.
As of Nov 16, 2026, ANDA 78879 (Temozolomide), held by Heritage, was first approved by FDA on Mar 1, 2010, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 1, 2010 | Original application | Approved |
| Temozolomide5MG · capsule;oral | Temozolomide | Discontinued |
| Temozolomide20MG · capsule;oral | Temozolomide | Discontinued |
| Temozolomide100MG · capsule;oral | Temozolomide | Discontinued |
| Temozolomide250MG · capsule;oral | Temozolomide | Discontinued |
| Temozolomide140MG · capsule;oral | Temozolomide | Discontinued |
| Temozolomide180MG · capsule;oral | Temozolomide | Discontinued |
| Apr 20, 2022 | Supplement 18Labeling · Standard review | Approved | None posted |
| Nov 14, 2019 | Supplement 15Labeling · Standard review | Approved | None posted |
| Nov 23, 2015 | Supplement 13Labeling · Standard review | Approved | None posted |
| Nov 23, 2015 | Supplement 12Labeling · Standard review | Approved | None posted |
| Nov 23, 2015 | Supplement 11Labeling · Standard review | Approved | None posted |
| Apr 30, 2013 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 13, 2011 | Supplement 4Labeling | Approved | None posted |
| Jul 28, 2010 | Supplement 1Labeling | Approved | None posted |
| Mar 1, 2010 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters